Related Experiment Video

Updated: Jun 5, 2025

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis
06:03

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis

Published on: May 9, 2025

211

The role of TRP channels in lung fibrosis: Mechanisms and therapeutic potential

M Ratnasingham1, P Bradding1, K M Roach1

  • 1NIHR Respiratory BRC, Department of Respiratory Sciences, University of Leicester, Leicester, UK.

The International Journal of Biochemistry & Cell Biology
|December 13, 2024
PubMed

Insights

Idiopathic pulmonary fibrosis (IPF) is a severe lung disease. Targeting transient receptor potential (TRP) channels may offer new therapeutic strategies by reducing lung scarring and fibrosis.

Area of Science:

  • Pulmonary Medicine
  • Cell Biology
  • Pharmacology

Background:

  • Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease with poor prognosis.
  • Current treatments for IPF offer limited efficacy, highlighting the need for novel therapeutic approaches.
  • IPF pathogenesis involves myofibroblast accumulation and excessive extracellular matrix deposition, leading to lung scarring.

Purpose of the Study:

  • To investigate the role of transient receptor potential (TRP) channels in IPF pathogenesis.
  • To explore the potential of TRP channel inhibition as a therapeutic strategy for IPF.

Main Methods:

  • Review of recent preclinical studies on TRP channels (TRPV4, TRPC6, TRPA1) in the context of fibrosis.
  • Analysis of TRP channel involvement in calcium signaling and mechanical stress-induced myofibroblast activation.

Main Results:

  • TRP channels are implicated in regulating calcium signaling and mechanical stress, key factors in myofibroblast activation.
  • Preclinical evidence suggests that inhibiting TRP channels can reduce fibrosis in models of lung disease.

Conclusions:

  • TRP channels represent a promising therapeutic target for IPF and other fibrotic lung diseases.
  • Further clinical trials are warranted to evaluate the safety and efficacy of TRP channel inhibitors in IPF patients.
Keywords:
FibrosisIdiopathic Pulmonary FibrosisIon channelsTherapeutic targetsTransient receptor potential (TRP) channels

More Related Videos

A Mouse Model of Pulmonary Fibrosis Induced by Nasal Bleomycin Nebulization02:46

A Mouse Model of Pulmonary Fibrosis Induced by Nasal Bleomycin Nebulization

Published on: January 20, 2023

3.5K
Generation of Human 3D Lung Tissue Cultures 3D-LTCs for Disease Modeling05:47

Generation of Human 3D Lung Tissue Cultures 3D-LTCs for Disease Modeling

Published on: February 12, 2019

20.5K

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
141
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
2.4K
Chronic Obstructive Pulmonary Disease-II: Pathophysiology01:20

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
2.7K
Mechanically-gated Ion Channels01:12

Mechanically-gated Ion Channels

Mechanically-gated ion channels are proteins found in eukaryotic and prokaryotic cell membranes that open in response to mechanical stress. Tension, compression, swelling, and shear stress can alter the conformation of the protein, opening a transmembrane channel that allows the passage of ions for signal transmission. In eukaryotes, mechanically-gated channels are distributed in several regions like the neurons, lungs, skin, bladder, and heart, where they play critical roles in numerous...
6.2K
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
141
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
147